Current Affiliation Organization 【 display / non-display 】

Current Affiliation Organization 【 display / non-display 】

University 【 display / non-display 】

University 【 display / non-display 】

External Career 【 display / non-display 】

External Career 【 display / non-display 】

display all >>

Affiliated academic organizations 【 display / non-display 】

Affiliated academic organizations 【 display / non-display 】

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

Published Papers 【 display / non-display 】

Published Papers 【 display / non-display 】

• Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer.

  Tanaka K, Hirakawa H, Suzuki M, Higa T, Agena S, Hasegawa N, Kawakami J, Toyama M, Higa T, Kinjyo H, Kise N, Kondo S, Maeda H, Ikegami T

  Current oncology (Toronto, Ont.) ( Current Oncology )  30 ( 6 ) 5409 - 5424   2023.06 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  In recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC), survival outcomes are significantly better in patients who receive anti-programmed cell death-1 (PD-1) monoclonal antibody therapy than in those who receive standard therapy. However, there is no established biomarker that can predict the anti-PD-1 antibody treatment effect and immune-related adverse events (irAEs) in these patients. This study investigated the inflammatory and nutritional status in 42 patients with R/M-HNSCC and programmed cell death ligand-1 (PD-L1) polymorphisms (rs4143815 and rs2282055) in 35 of the 42 patients. The 1- and 2-year overall survival was 59.5% and 28.6%, respectively; the 1- and 2-year first progression-free survival was 19.0% and 9.5%, respectively, and the respective second progression-free survival was 50% and 27.8%. Performance status and inflammatory and nutritional status (assessed by the geriatric nutritional risk index, modified Glasgow prognostic score, and prognostic nutritional index) were identified as significant indicators of survival outcomes in multivariate analysis. Patients with ancestral alleles in PD-L1 polymorphisms had less frequent irAEs. Performance status and inflammatory and nutritional status before treatment were closely related to survival outcomes after PD-1 therapy. These indicators can be calculated using routine laboratory data. PD-L1 polymorphisms may be biomarkers for predicting irAEs in patients receiving anti-PD-1 therapy.

  • Access this article
    DOI
  • Search related information
    PubMed

• Human Papillomavirus Infection and EGFR Exon 20 Insertions in Sinonasal Inverted Papilloma and Squamous Cell Carcinoma.

  Hirakawa H, Ikegami T, Kise N, Kinjyo H, Kondo S, Agena S, Hasegawa N, Kawakami J, Maeda H, Suzuki M

  Journal of personalized medicine ( Journal of Personalized Medicine )  13 ( 4 ) 657   2023.04 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI
  • Search related information
    PubMed

• Distribution pattern and pathologic analysis of metastatic sentinel and non-sentinel lymph nodes in lymphatic basin dissection for clinical T2/T3 oral cancer with clinical N0 status.

  Hirakawa H, Matsuzuka T, Uemura H, Yoshimoto S, Miura K, Shiotani A, Sugasawa M, Homma A, Yokoyama J, Tsukahara K, Yoshizaki T, Hanai N, Suzuki H, Suzuki M, Hasegawa Y

  Auris, nasus, larynx ( Auris Nasus Larynx )  49 ( 4 ) 680 - 689   2022.08 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  OBJECTIVE: The localization pattern of metastatic sentinel lymph node (SN) and non-SNs and pathologic analysis of metastatic lymph nodes in SN lymphatic basin dissection (SLBD) were investigated in patients with cT2/T3cN0 oral squamous cell carcinoma (OSCC). METHODS: This prospective multicenter trial involved 10 institutions nationwide in Japan. A total of 57 patients were enrolled. The lateral neck was divided into 5 lymphatic basins. The lymphatic basin containing SNs was defined as the SN lymphatic basin. All patients underwent SLBD with backup selective neck dissection (I-III) combined with primary tumor removal. When SNs were found outside of levels I-III, including in the contralateral neck, SLBD was performed by removing the compartments containing SNs separately. SN metastasis was classified as isolated tumor cells (ITCs), micrometastasis, or macrometastasis. ITCs are defined as a lesion no larger than 0.2 mm in largest dimension and are classified as pN0. RESULTS: SN metastasis was observed in 22 cases. All metastatic lymph nodes, including false-negative cases, were detected in the SN lymphatic basin. Isolated tumor cells in the SNs did not affect prognosis, whereas micrometastasis tended to have poor prognosis. After adjusting for other risk factors, a positive SN remained a significant predictor of poor 5-year overall survival in pT2-4 OSCC. CONCLUSION: SLBD for intraoperative SN biopsy is a sufficient therapeutic procedure and is valuable for determining pathologic nodal stage in OSCC. SN positivity was demonstrated to be an independent predictor of poor prognosis in patients with pT2-4 disease undergoing SLBD with backup selective neck dissection (I-III).

  • Access this article
    DOI
  • Search related information
    PubMed

• Prognostic significance of hypoxia-inducible factor-1α expression in advanced pharyngeal cancer without human papillomavirus infection.

  Agena S, Hirakawa H, Ikegami T, Kinjyo H, Kise N, Maeda H, Uezato J, Kondo S, Kiyuna A, Yamashita Y, Hasegawa N, Suzuki M, Ganaha A

  The Journal of laryngology and otology ( Journal of Laryngology and Otology )  135 ( 7 ) 625 - 633   2021.07 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  OBJECTIVE: This study aimed to clarify the association between both hypoxia-inducible factor-1α and glucose transporter type-1 expression and survival outcome in advanced pharyngeal cancer without human papillomavirus infection. METHOD: Twenty-five oropharyngeal and 55 hypopharyngeal cancer patients without human papillomavirus infection were enrolled. All patients had stage III-IV lesions and underwent concurrent chemoradiotherapy or surgery. Hypoxia-inducible factor-1α and glucose transporter type-1 expression were investigated in primary lesions by immunohistochemistry. RESULTS: There were 41 and 39 cases with low and high hypoxia-inducible factor-1α expression, and 28 and 52 cases with low and high glucose transporter type-1 expression, respectively. There was no significant correlation between hypoxia-inducible factor-1α and glucose transporter type-1 expression. In univariate analysis, nodal metastasis, clinical stage and high hypoxia-inducible factor-1α expression, but not glucose transporter type-1 expression, predicted significantly worse prognosis. In multivariate analysis, hypoxia-inducible factor-1α overexpression was significantly correlated with poor overall survival, disease-specific survival and recurrence-free survival. CONCLUSION: High hypoxia-inducible factor-1α expression was an independent risk factor for poor prognosis for advanced human papillomavirus-unrelated pharyngeal cancer.

  • Access this article
    DOI
  • Search related information
    PubMed

• One-Stage Cochlear Implantation for Adhesive Otitis Media

  Higa Teruyuki, Ganaha Akira, Kondo Shunsuke, Oyakawa Yoshiki, Agena Shinya, Hirakawa Hitoshi, Suzuki Mikio

  Practica Oto-Rhino-Laryngologica ( The Society of Practical Otolaryngology )  114 ( 12 ) 909 - 916   2021

  Type of publication: Research paper (scientific journal)

  　View Summary

  <p>Cochlear implant surgery has been introduced successfully and is now one of the commonly performed surgeries. However, the surgical strategy of cochlear implantation in patients with chronic middle ear diseases, such as chronic otitis media and cholesteatoma, has not yet been fully established. In the present report, we describe the surgical technique adopted and prognosis of two patients with severe adhesive otitis media who underwent cochlear implant surgeries. Both underwent one-stage cochlear implantation combined with external auditory canal closure (blind-sac closure). Mastoidectomy with removal of the whole canal wall was performed to remove the otitis lesion thoroughly, and external auditory canal wall closure was performed to prevent recurrence of the lesion. A pneumatized tympanic cavity was observed and canal wall closure was maintained in both cases. Both patients acquired fair hearing ability with the cochlear implants. No severe complications have occurred until now, four years since the cochlear implantation. Although external ear canal closure destroys the natural structure of the external ear, one-stage cochlear implant surgery combined with canal closure is useful for elderly patients with systemic complications who desire shortening of hearing-deprived period.</p>

  • Access this article
    DOI
  • Search related information
    CiNii Research

display all >>

Books 【 display / non-display 】

Books 【 display / non-display 】

• Practice of oro-parynx

  Hirakawa Hitoshi ( Part: Multiple Authorship )

  2015.09

Other Papers 【 display / non-display 】

Other Papers 【 display / non-display 】

• DNA修復酵素遺伝子多型による導入化学療法の効果予測

  平川 仁, 山下 懐, 上原 貴行, 安慶名 信也, 上里 迅, 金城 秀俊, 真栄田 裕行, 鈴木 幹男

  頭頸部癌 ( (一社)日本頭頸部癌学会 )  45 ( 2 ) 220 - 220   2019.05

   

• 頭頸部扁平上皮癌再発例に対する動注療法の検討

  安慶名 信也, 平川 仁, 真栄田 裕行, 鈴木 幹男, 平安名 常一

  頭頸部癌 ( (一社)日本頭頸部癌学会 )  45 ( 2 ) 238 - 238   2019.05

   

• 当科における頭頸部原発不明癌の検討

  真栄田 裕行, 嘉陽 祐紀, 金城 秀俊, 上里 迅, 安慶名 信也, 上原 貴行, 山下 懐, 平川 仁, 鈴木 幹男

  頭頸部癌 ( (一社)日本頭頸部癌学会 )  45 ( 2 ) 165 - 165   2019.05

   

• 側頸嚢胞におけるハイリスク型・ヒトパピローマウイルス-16の感染

  池上 太郎, 上原 貴行, 平川 仁, 真栄田 裕行, 我那覇 章, 鈴木 幹男

  耳鼻咽喉科ニューロサイエンス ( 耳鼻咽喉科ニューロサイエンス研究会 )  33   75 - 79   2019.05

   

• DNA修復酵素遺伝子多型と頭頸部癌の予後予測

  平川 仁, 山下 懐, 上原 貴行, 比嘉 朋代, 當山 昌那, 嘉陽 祐紀, 鈴木 幹男

  日本耳鼻咽喉科学会会報 ( (一社)日本耳鼻咽喉科学会 )  122 ( 4 ) 711 - 711   2019.04

   

display all >>

Academic Awards 【 display / non-display 】

Academic Awards 【 display / non-display 】

• Surgical Leadership Program, Team Assigment Awards

  2023.03   Harvard Medical School  

• Best Paper Award of JSHNC

  2019.06   Japan Society for Head and Neck Cancer   Symptom prevalence and functional status in patient with terminal phase of head and neck cancer: multi-institutional research

  Winner: Hirakawa Hitoshi

  　View Summary

  There have been a limited number of studies about clinical symptoms in patients with terminal phase of head and neck cancers. The aim of this prospective multi-institutional study (11 institutes) was to assess the prevalence of symptoms and functional status among patients with advanced head and neck cancer. Of the 100 patients who met the inclusion criteria, 72 patients were observed until their death. Neck dressing treatment was needed for skin-infiltration symptoms, such as bleeding, infection, and exudation in 30.6% of patients at study entry and in 36.1% just before death. Severe bleeding causing death was observed in 6.9% of patients and the lethal rupture of carotid artery was in only one case (1.4%). At the time of study entry, 75% of patients kept enteral nutrition, and 61.1% still received enteral nutrition just before death. Laryngeal phonation ability was not kept in 44.4% of patients at the time of study entry and 50% just before death. Edema in head and neck region was observed in 23.6% of patients at entry and 36.1% at the time of death. Since the above mentioned symptoms in patients with terminal phase were not mild, these symptoms sometimes cause uneasiness in head and neck patients, their families, and the medical staffs. To relieve anxiety of patients, families, and the medical staffs, further large scale prospective studies are needed to establish care management of head and neck cancer patients with terminal phase and bring the better quality of life at terminal phase.

• Award for life science project

  2018.10     Prognostic impact of DNA repair gene polymorphism in head and neck cancer patients

  Winner: Hirakawa Hitoshi

• Award for achievements, Ryukyu university medical faculty

  2018.01   University of Ryukyus  

  Winner: Hirakawa Hitoshi

Grant-in-Aid for Scientific Research 【 display / non-display 】

Grant-in-Aid for Scientific Research 【 display / non-display 】

• Development of minimally invasive treatment in head and neck cancer focused on PI3K/Akt/mTOR pathway

  Grant-in-Aid for Scientific Research(C)

  Project Year: 2021.04  -  2024.03 

  Direct: 3,200,000 (YEN)  Overheads: 4,160,000 (YEN)  Total: 960,000 (YEN)

• Genetic polymorphisms and lifestyle related to head and neck cancer development

  Grant-in-Aid for Scientific Research(C)

  Project Year: 2021.04  -  2024.03 

  Direct: 3,200,000 (YEN)  Overheads: 4,160,000 (YEN)  Total: 960,000 (YEN)

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2020.04  -  2023.03 

  Direct: 3,400,000 (YEN)  Overheads: 4,420,000 (YEN)  Total: 1,020,000 (YEN)

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2017.04  -  2020.03 

  Direct: 3,600,000 (YEN)  Overheads: 1,080,000 (YEN)  Total: 4,680,000 (YEN)

• Do not miss head and neck small cancer: establishment of micro cancer identification method with a novel fluorescent probe

  Grant-in-Aid for challenging Exploratory Research

  Project Year: 2016.04  -  2018.03 

  Investigator(s): Ikegami Taro 

  Direct: 2,700,000 (YEN)  Overheads: 3,510,000 (YEN)  Total: 810,000 (YEN)

  　View Summary

  This study aims to validate whether the head and neck microcancer can be visualized using novel fluorochrome probe, Proteogreen to completely eliminate head and neck cancer in the operation in the future. We succeeded in visualization with some head and neck cancers. However, normal glandular tissue, fibrous connective tissue, cartilage and lymphocytes were also visualized in almost tumors. The further study will be required for establishment of intraoperative imaging with this probe.